The clinical development of paclitaxel: A successful collaboration of academia, industry and the National Cancer Institute

Research output: Contribution to journalReview article

Abstract

The successful development of paclitaxel as an important new antineoplastic agent with the potential to have an impact on a number of human cancers was possible as a result of significant contributions from individuals and groups with diverse areas of interest and expertise. The advancement of paclitaxel through the preclinical and clinical evaluation which ultimately led to its approval, as well as surmounting the regulatory hurdles which were faced required the close collaboration of individual investigators at academic institutions, the pharmaceutical industry (Bristol- Myers Squibb) and the National Cancer Institute. The latter stages of this developmental effort can be viewed as a prime example of the potential of the Cooperative Research and Development Agreement (CRADA) mechanism to bring novel therapies to patients with serious illnesses in a timely fashion. It is also tangible evidence of the vision and perseverance of a number of members of the Division of Cancer Treatment (DCT) under the direction of Dr. Bruce Chabner, in whose honor this symposium is given.

Original languageEnglish (US)
Pages (from-to)25-28
Number of pages4
JournalStem Cells
Volume14
Issue number1
DOIs
StatePublished - 1996

Keywords

  • Cisplatin
  • Cytotoxicity
  • Paclitaxel
  • Taxol®
  • Tubulin

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'The clinical development of paclitaxel: A successful collaboration of academia, industry and the National Cancer Institute'. Together they form a unique fingerprint.

Cite this